In the October issue of The Oncology Nurse-APN/PA (TON), we feature a variety of articles aimed at informing and empowering nurses, navigators, and advanced practice providers who work to improve the lives of patients with cancer.
We begin this issue with an interview with Kellie Zeichner, RN, BSN, OCN, Nurse Clinician Infusion Educator, Rutgers Cancer Institute of New Jersey, New Brunswick, who discusses her role in providing education and support to nurses at her center, some of the challenges and rewards of her job, and how the development and approval of new agents are increasing treatment options for patients with cancer (see here).
This issue of TON also includes coverage from national and international oncology meetings, where experts presented safety and efficacy data on novel anticancer regimens as well as new approaches aimed at reducing adverse events and improving patient quality of life.
During the European Society for Medical Oncology Congress 2022, a panel of renowned physicians discussed effective strategies for identifying and minimizing distressing symptoms associated with cancer and its treatment—namely, cachexia, emotional and cognitive issues, fatigue, dyspnea, and cough (see here).
In another informative session, nursing professionals from several countries came together to share their insights on how best to support and empower young oncology nurses academically, clinically, and professionally (see here).
Rounding out our coverage from the meeting, we feature highlights from a keynote lecture by Deb Schrag, MD, MPH, who discussed the current landscape and future directions of digital health technologies in oncology care (see here).
This issue of TON also includes highlights of several sessions from the 2022 American Society of Clinical Oncology Annual Meeting. In a particularly encouraging presentation made during the meeting, Timothy Joseph Whelan, MD, FASCO, discussed findings from the LUMINA study, which suggest that radiation therapy may be safely omitted in select patients aged ≥55 years with low-grade luminal type A breast cancer (see here).
In a separate presentation, Sara M. Tolaney, MD, MPH, and colleagues, provided details from a multivariate analysis of the MonarchE study, which identified key factors associated with early discontinuation of abemaciclib in patients with hormone-receptor–positive, HER2-negative breast cancer. The results of this analysis highlight the importance of closely monitoring patients receiving this agent and knowing how to initiate appropriate interventions, such as dose adjustments, to allow continuation of therapy (see here).
Additional topics in this issue include recent advances in the treatment of several other malignancies, including multiple myeloma, lymphoma, cervical cancer, and cholangiocarcinoma.
As always, we hope that you will enjoy this issue of TON, and we invite you to visit www.TheOncologyNurse.com to share your feedback with us. You can also send an e-mail with any questions or comments you may have to info@TheOncologyNurse.com.
To sign up for our newsletter or print publications, please enter your contact information below.
Subscribe to recieve the free, monthly TON print publication and TON weekly e‑newsletter.